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Plasma Cardiac Troponin I Concentration and Cardiac Death in
Cats with Hypertrophic Cardiomyopathy
K. Borgeat, K. Sherwood, J.R. Payne, V. Luis Fuentes, and D.J. Connolly
Background: The use of cardiac biomarkers to assist in the diagnosis of occult and symptomatic hypertrophic cardio-
myopathy (HCM) in cats has been established. There is limited data describing their prognostic utility in cats with HCM.
Hypothesis: Circulating concentrations of N-terminal B-type natriuretic peptide (NTproBNP) and cardiac troponin I
(cTnI) predict cardiac death in cats with HCM.
Animals: Forty-one cats diagnosed with HCM at a veterinary teaching hospital, between February 2010 and May
2011.
Methods: Prospective investigational study. Plasma samples were collected from cats diagnosed with HCM and concen-
trations of NTproBNP and cTnI were analyzed at a commercial laboratory. Echocardiographic measurements from the
day of blood sampling were recorded. Long-term outcome data were obtained. Associations with time to cardiac death
were analyzed using Cox proportional hazards models.
Results: When controlling for the presence/absence of heart failure and echocardiographic measures of left atrial size
and function, cTnI > 0.7 ng/mL was independently associated with time to cardiac death. In univariable analysis,
NTproBNP > 250 pmol/L was associated with cardiac death (P = .023), but this did not remain significant (P = .951)
when controlling for the effect of clinical signs or left atrial size/function.
Conclusions and Clinical Importance: Plasma concentration of cTnI (cutoff >0.7 ng/mL) is a predictor of cardiac death
in cats with HCM that is independent of the presence of heart failure or left atrial dilatation.
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Hypertrophic cardiomyopathy (HCM) is the mostcommon cardiac disease in cats.1–6 It also affects
1 in 500 people and is the most frequent cause of car-
diac death in young adults.7 Prognostic indicators have
been identified in both humans and cats.4,8–10 In
humans, independent predictors of death because of
cardiac disease include family history of cardiac death,
nonsustained ventricular tachycardia, severe hypertro-
phy (≥30 mm) of the left ventricular (LV) wall, LV
outflow tract obstruction, late gadolinium enhance-
ment on magnetic resonance imaging and younger age
at diagnosis.11–13 Poor prognostic indicators for cats
with HCM include arterial thromboembolism (ATE),
congestive heart failure (CHF), increased left atrial
(LA) size, decreased LA and LV systolic function, and
LV hypertrophy ≥9 mm.4,10,14,15
The use of circulating cardiac troponin I (cTnI) and
N-terminal pro-B-type natriuretic peptide
(NTproBNP) concentrations to assist diagnosis, guide
treatment, and screen individuals for HCM has
recently received much attention in human and veteri-
nary cardiology research.16–25 However, little informa-
tion is available on the prognostic value of circulating
biomarker concentrations in HCM. A single measure-
ment of NTproBNP, cardiac troponin, or a combina-
tion of both, act as independent predictors of adverse
cardiovascular events, including death because of car-
diac disease, in human patients with HCM.26–29 One
study in cats with heart failure suggested that
increased NTproBNP concentrations predicted survival
to 1 month after diagnosis of CHF,a while another
recent study suggested that troponins I and T are asso-
ciated with cardiac death in pedigree cats with
HCM.30
The primary aim of this study was to determine if a
single measurement of circulating NTproBNP, cTnI,
or both, in cats of any breed diagnosed with HCM
could provide useful prognostic information. We
hypothesized that increases in both NTproBNP and
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Abbreviations:
ATE arterial thromboembolism
CHF congestive heart failure
cTnI cardiac troponin I
HCM hypertrophic cardiomyopathy
HR heart rate
LA : Ao ratio of left atrium to aortic root diameter (short-
axis)
LAD maximum left atrial diameter (long-axis)
LAEF left atrial ejection fraction
LAFS left atrial fractional shortening
LA left atrial/atrium
LVIDd left ventricular internal diameter in diastole
LV left ventricular
MST median survival time
NTproBNP N-terminal pro-B type natriuretic peptide
RR respiratory rate
SAM systolic anterior motion of the mitral valve
SBP systolic blood pressure (Doppler)
T4 total thyroxine
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cTnI would be significantly associated with reduced
time to cardiac death.
Materials and Methods
Animals
Cats presented to a veterinary teaching hospitalb for investiga-
tion of heart disease from February 2010 to May 2011 were eligi-
ble for prospective enrollment. The inclusion criteria were a
diagnosis of HCM on 2-dimensional (2D) echocardiography and
a blood sample taken within 24 hours of presentation, from
which residual EDTA plasma was available. Echocardiography
was performed by a Diplomate in Cardiology or Resident under
supervision. Exclusion criteria were any diagnosis other than
HCM; chronic kidney disease (IRIS Stage >II) or other signifi-
cant systemic disease; cats ≥8 years old without a recorded blood
pressure or where total thyroxine (T4) concentration was unavail-
able. In addition, cats with other possible causes of LV hypertro-
phy such as hyperthyroidism, hypertension, or clinical evidence
of hypovolemia (“pseudohypertrophy”) were excluded.
Clinical Data
At presentation age, sex, breed, heart rate (HR), respiratory
rate (RR), weight, and systolic blood pressure (SBP) were
recorded. Echocardiographic measurements were performed at
the time of presentation to the clinic and later reviewed by a sin-
gle cardiologist (DJC). A maximum diastolic LV free wall or in-
terventricular septum measurement of ≥6 mm was considered
diagnostic for HCM.1,6 The ratio of LA diameter to aortic root
(LA : Ao) was measured from a 2D short axis view at the heart
base, optimized for the LA and aortic valve, in the frame before
aortic valve opening (end-ventricular diastole) using an inner
edge to inner edge technique.31 Maximum LA diameter (LAD)
was measured from the 2D right parasternal long-axis view
(RPLA), in the frame before mitral valve opening (end-ventricu-
lar systole).32 LV internal diameter in diastole (LVIDd) was mea-
sured in 2D from the RPLA, in the first frame in which the
mitral valve was closed. M-mode measurements LV fractional
shortening (LVFS) and LA fractional shortening (LAFS) were
made using a leading edge to leading edge method.10,33,34 LA
ejection fraction (LAEF) was measured in the 2D RPLA, opti-
mized for the LA, using a modified Simpson’s method.10,33,34
Transmitral flow velocities (E and A waves) were recorded from
pulsed wave Doppler interrogation of diastolic mitral inflow in
the left-apical 4-chamber view.35 Waves were considered sum-
mated at an E-at-A intersection velocity >0.25 m/s. The presence
of mitral systolic cranial motion, regional LV wall hypokinesis,
and restrictive mitral inflow pattern (E : A ratio > 2, nonsum-
mated36) were recorded as categorical variables (yes/no). Regio-
nal hypokinesis was defined as localized subjective lack of
systolic excursion with thinning of a segment of LV wall.10
Congestive heart failure was defined as present if the cat had
radiographic or ultrasonographic evidence of cardiogenic pulmo-
nary edema or pleural effusion in the presence of LA dilatation
(LA : Ao ≥ 1.5,31 LAD ≥ 16 mm,32 or both), or tachypnea
responsive to furosemide in the presence of LA dilatation
(LA : Ao ≥ 1.5,31 LAD ≥ 16 mm,32 or both). If another poten-
tial cause of pleural effusion (eg, intrathoracic neoplasia) was
present, the cat was excluded from the study.
Cardiac Biomarkers
Residual EDTA plasma samples were obtained after jugular
venipuncture for clinical purposes. Samples were processed within
20 minutes of collection. Plasma was separated by centrifuga-
tion at 800 9 g for 3 minutes, immediately before storage at
80°C. After transport on dry ice to a commercial veterinary
laboratory,c batch analysis of NTproBNP and cTnI (using a high
sensitivity assayd ) was performed. The lower limit of detection
was 24 pmol/L for the NTproBNP assay37 and 0.01 ng/mL for
the cTnI assay. For the purposes of statistical analysis, results
below these limits were recorded as 24 pmol/L and 0.01 ng/mL
respectively.
Outcome
The end of the study period was September 1, 2013. Owners
of cats were contacted annually, according to a protocol
approved by the institutional ethics committee. Owners were sent
a letter and questionnaire, followed by a telephone call if no
response was received within 30 days. Primary veterinarians were
contacted regarding the circumstances of death if euthanasia was
performed. The end-point of the study was death, categorized as
death because of cardiac disease or noncardiac causes. Cardiac
causes included death or euthanasia because of clinical signs of
CHF or ATE, or sudden death unrelated to known systemic dis-
ease or trauma. Noncardiac causes were death or euthanasia
after clinical signs not attributable to heart disease (eg, vomiting,
diarrhea, trauma, or diagnosed neoplasia).
Statistical Analysis
Statistical analysis was performed using commercially avail-
able software.e For continuous data, normality was assessed
graphically and using a Shapiro–Wilk test. Normally distributed
continuous data (represented mean  SD) were compared using
an independent samples t-test and nonnormally distributed data
(represented median and range) were compared using a Mann–
Whitney U-test. To look for linear correlation between two
continuous variables, Spearman’s rank correlation (qs) was
used.
The end-point for survival analysis was death because of car-
diac disease. Animals dying of noncardiac disease or alive at the
end of the study period were right-censored for survival analysis.
Univariable time-to-event models were constructed using Cox
proportional hazards analysis. Continuous variables were initially
analyzed as quintiles (cTnI) or quartiles (all others) using Kap-
lan–Meier curves and pairwise Log-rank tests. Variables where
hazard increased ordinally were eligible for inclusion in time-to-
event analysis as continuous variables. Where one or more
groups had disproportionately different hazards to the others,
these variables were presumed to exhibit a threshold effect, and
were included in Cox models as categorical variables using a cut-
off established by the exceptional quartile/quintile.
Multivariable analysis was performed in a forwards stepwise
manner, to investigate the association of cardiac biomarkers
with time to death because of cardiac disease. Variables signifi-
cant at P < .2 at the univariable level were carried forward to
multivariable Cox analysis. The assumptions of Cox propor-
tional hazards were tested using log cumulative hazard plots
and Schoenfeld residuals, and overall model fit was evaluated
using Cox Snells. Where variables showing statistically signifi-
cant correlation were included in a model, a variance inflation
factor (VIF) were calculated for each pair of correlated vari-
ables. Colinearity was considered insignificant for the purposes
of Cox multivariable analysis if the VIF was <10. Aikaike’s
information criteria were calculated for each of the final multi-
variable Cox models to assess ability of the overall model to
explain difference in time to cardiac death. Statistical
significance was set at P < .05.
2 Borgeat et al
Results
Population
Fifty-nine cats were eligible for inclusion. Eighteen
were excluded because of hyperthyroidism (2), non-
HCM cardiac disease (8), or no diagnosis of heart dis-
ease (8), leaving 41 cats that met the inclusion criteria.
Population characteristics, clinical data and echocar-
diographic measurements are summarized in Table 1.
At the end of the study period, 24/41 cats (59%)
had died, 17 (41%) were alive and none were lost to
follow-up. Death was considered to be because of car-
diac disease in 21/24 cats (ie, 51% of the entire study
population reached the primary end-point). Cardiac
causes of death were euthanasia because of CHF (14),
euthanasia because of clinical signs of ATE (2), sudden
death associated with dyspnea (3) and sudden death
after clinical signs of limb ATE (2). Noncardiac causes
of death were euthanasia because of advanced chronic
kidney disease (2) and mediastinal lymphoma (1).
Associations between Biomarkers and Clinical/
Echocardiographic Findings
There was significant but weak correlation between
cTnI and LA : Ao (qs 0.50), LAD (qs 0.42), LAFS (qs
0.49), LAEF (qs 0.48), LVFS (qs 0.47), weight (qs
0.44), and NTproBNP (qs 0.46). VIF for each of these
significant correlations was <10 (1.10–7.58), suggesting
that colinearity was not great enough to impact upon
multivariable Cox proportional hazards analysis. There
was no correlation between age, HR, RR, maximum
LV thickness, or LVIDd. cTnI (but not NTproBNP)
concentrations were significantly higher in cats with
regional LV wall hypokinesis than those without
(0.99 ng/mL, 0.3–4.56 ng/mL; versus 0.2 ng/mL, 0.01–
3.8 ng/mL; P = .027). All 6 cats with regional hypoki-
nesis had the inferior LV free wall affected.
NTproBNP was significantly correlated with
LA : Ao (qs 0.63), LAD (qs 0.57), LAFS (qs 0.77),
LAEF (qs 0.69), LVFS (qs 0.42), and SBP (qs
0.47). VIF for each of these significant correlations
was <10 (1.64–5.73), suggesting that colinearity was
not great enough to impact upon multivariable Cox
proportional hazards analysis. There was no correla-
tion between age, weight, HR, RR, maximum LV
thickness, or LVIDd. Cats with CHF had significantly
higher median NTproBNP concentration than those
without (569 pmol/L, 126–1,451 pmol/L; versus
249 pmol/L, 24–786 pmol/L; P = .016).
Among echocardiographic variables, significant cor-
relation was present between LA : Ao and LAD (qs
0.87), LAEF (qs 0.81), LAFS (qs 0.85), and LVFS
(qs 0.60). In addition, LAD was correlated with LAEF
(qs 0.74), LAFS (qs 0.75), and LVFS (qs 0.58);
LAFS with LAEF (qs 0.84) and LVFS (qs 0.54); and
Table 1. Population characteristics, clinical data, and echocardiographic findings of the 41 cats enrolled in the
study.
Parameter Alive or Noncardiac Death Cardiac Death P-Value
Number of cats 20 21 –
Follow-up period (days) 1,050 (162–1,274) 241 (2–946) <.001*
Age (years) 6.2 (0.96–16.4) 6.9 (0.72–16.1) .873
Male, n (%) 12/20 (60) 16/21 (76) .244
Purebred, n (%) 4/20 (20) 8/21 (38.1) .177
Body weight (kg) 4.2 (2.6–5.6) 4.43 (2.77–6.34) .589
Heart rate (per minute) 184  36 180  35 .666
Respiratory rate (per minute) 39  14 46  16 .259
CHF confirmed, n (%) 5/20 (25) 19/21 (90.5) <.001*
Systolic blood pressure (mmHg) 140  22 121  20 .013*
NTproBNP (pmol/L) 266 (24–786) 573 (24–1,451) .008*
cTnI (ng/mL) 0.11 (0.01–0.73) 0.27 (0.05–4.56) .527
LA : Ao ratio 1.52  0.34 2.51  0.76 <.001*
LA maximum diameter (mm) 16.2  3.98 23.7  3.61 <.001*
LA fractional shortening (%) 29 (7.69–46.2) 8.54 (2.94–31.3) <.001*
LA ejection fraction (%) 53.5 (1.18–67.6) 16.4 (5.13–60.1) <.001*
LV fractional shortening (%) 54.5  12.9 36.3  13.1 <.001*
IVSd (mm) 6.70  1.37 5.84  2.00 .198
LVFWd (mm) 7.13  1.60 6.91  2.50 .794
LV maximum thickness (mm) 7.74  1.14 7.69  1.35 .915
SAM present, n (%) 13/20 (65) 8/21 (38.1) .121
Restrictive mitral inflow present, n (%) 3/17 (17.6) 7/10 (70) .013*
Regional LV hypokinesis present, n (%) 0/20 (0) 6/21 (28.6) .021*
CHF, congestive heart failure; NTproBNP, N-terminal of pro-B-type natriuretic peptide; cTnI, cardiac troponin I; LA : Ao, left
atrium to aortic root ratio; LA, left atrial/atrium; LV, left ventricular; IVSd, interventricular septum measured at end-diastole; LVFWd,
left ventricular free wall measured at end-diastole; SAM, systolic anterior motion of the mitral valve.
*Indicates variables significantly different between cats suffering a cardiac death and those that died a noncardiac death or alive at the
end of the study period. Normally distributed data are represented as mean  SD, and nonnormally distributed data are represented as
median (range).
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LAEF with LVFS (qs 0.62, P < .05 for each pairwise
correlation listed). SBP was correlated with LAFS (qs
0.57). These significant interactions were considered
when performing multivariable Cox proportional haz-
ards analysis.
Survival Analysis
Median survival time (MST) to cardiac death for
the whole population was >946 days. Median follow-
up period was 834 days (2–1,274 days). Cats with cTnI
>0.7 ng/mL had a significantly shorter MST (40 days,
95% CI 0–168 days; versus >1,274 days, P = .001;
Fig 1). Cats with NTproBNP > 250 pmol/L also had a
significantly shorter MST than those with
NTproBNP ≤ 250 pmol/L (764 days, 95% CI 159–
1,369 days; versus >1,257 days, P = .005; Fig 1). A
combined measurement of NTproBNP > 250 pmol/L
and cTnI > 0.7 ng/mL did not yield additional infor-
mation regarding survival time when compared to
measurement of cTnI > 0.7 ng/mL alone.
The results of univariable Cox proportional hazards
analysis are shown in Table 2. Two models were
devised to evaluate the use of NTproBNP and cTnI as
predictors of time to cardiac death in multivariable
analysis. First, a model employing cardiac biomarkers
where the presence/absence of CHF is confirmed, but
echocardiography is unavailable. Second, a multivari-
able model was constructed where all data were eligi-
ble for inclusion (biomarkers, CHF present/absent,
and echocardiographic measurements).
In the first model, when controlling for the con-
firmed presence/absence of CHF, NTproBNP did not
provide additional prognostic value. However, cTnI
provided additional, independent predictive value of a
significantly shorter time to death because of cardiac
disease (Table 3). Other measured variables were not
significant.
In the second model, NTproBNP did not remain
predictive of shorter time to death because of cardiac
disease in any multivariable model featuring confirmed
CHF status and echocardiographic measurement of
LA size or function. Conversely, cTnI did provide
additional prognostic information even when account-
ing for the effect of LA size, LA function, or LV sys-
tolic function. However, if echocardiographic evidence
of regional LV hypokinesis was detected, cTnI lost sig-
nificance, suggesting some interrelationship. Detailed
evaluation of the echocardiographic data resulted in
the construction of 2 alternate final models (Table 3).
In one, CHF status, LA : Ao > 1.76 and
cTnI > 0.7 ng/mL were independent predictors of time
Fig 1. Kaplan–Meier curves to show the effect on survival of
cardiac biomarker concentrations at the univariable level.
NTproBNP, N-terminal pro-B type natriuretic peptide; cTnI, car-
diac troponin I.
Table 2. Variables associated (P < .2) with a shorter
time to cardiac death in univariable Cox proportional
hazards analysis.
Parameter HR 95% CI P-Value
Age
≥3.53 years Ref
<3.53 years 4.82 1.12–20.8 .035
LA : Ao
≤1.76 Ref.
>1.76 12.3 3.56–42.4 <.001
LA maximum diameter
≤16 mm Ref
>16 mm 16.3 2.18–122.2 .007
LA fractional shortening
≥14.2% Ref
<14.2% 7.8 2.58–23.5 <.001
LA ejection fraction
≥33.5% Ref
<33.5% 12.3 3.56–42.4 <.001
LV fractional shortening
≥47% Ref
<47% 5.49 1.98–15.2 .001
NTproBNP
≤250 pmol/L Ref
>250 pmol/L 10.4 1.39–77.6 .023
cTnI
≤0.7 ng/mL Ref
>0.7 ng/mL 4.77 1.68–13.5 .003
Systolic BP
≥130 mmHg Ref
<130 mmHg 3.08 1.13–8.44 .028
Regional LV hypokinesis
No Ref
Yes 35.9 6.69–192.5 <.001
Nonrestrictive mitral inflow Ref
Restrictive mitral inflow present 6.92 1.76–27.2 .006
Congestive heart failure
No Ref
Yes 15 3.4–66.4 <.001
HR, hazard ratio; 95% CI, 95% confidence intervals; LA : Ao,
left atrium to aortic root ratio; LA, left atrial; LV, left ventricu-
lar; NTproBNP, N-terminal of pro-B-type natriuretic peptide;
cTnI, cardiac troponin I.
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to cardiac death. In the other, CHF status and pres-
ence of regional LV hypokinesis were independent pre-
dictors of time to death because of cardiac disease.
Discussion
This prospective study demonstrates the long-term,
independent prognostic value of a single measurement
of cTnI in cats of any breed with HCM. One recent
study by demonstrated that pedigree cats suffering an
HCM-related death had higher cTnI at initial diagno-
sis than survivors.30 In our data, not only was
cTnI > 0.7 ng/mL associated with a shorter survival
time to cardiac death but also it had predictive value
in addition to the presence of CHF and LA dilatation.
In our study, higher NTproBNP was not an indepen-
dent predictor of cardiac death, but both increased
NTproBNP and cTnI concentrations were significantly
associated with a worse prognosis in univariable analy-
sis (cutoff values >250 pmol/L and >0.7 ng/mL respec-
tively). A combination of both biomarkers did not
provide additional prognostic information compared
to measurement of cTnI > 0.7 ng/mL alone.
The presence of CHF and LA dilatation are widely
acknowledged indicators of risk of cardiac death in
cats with HCM.4,14,15,38 Echocardiographic measures
of poor LA function, extreme LV hypertrophy, and
reduced LV systolic function were independent predic-
tors of shorter time to cardiac death in a large popula-
tion of cats with HCM.10 In our univariable analysis,
CHF status (present/absent), measures of LA size and
function, LV systolic function, the presence of restric-
tive mitral inflow, and regional LV hypokinesis were
significantly associated with time to death because of
cardiac disease (as previously reported10).
In multivariable analysis, to investigate whether car-
diac biomarker measurement could provide useful
additional prognostic information on survival when
the effects of CHF status and echocardiographic mea-
surements were accounted for, we derived two alter-
nate models to reflect different clinical situations,
where the clinician either has or does not have access
to echocardiographic information (for example, in
many general practice clinics). In the first model, mul-
tivariable analysis evaluated the prognostic value of bi-
omarkers where CHF was already confirmed as
present or absent. In this model, NTproBNP did not
remain significant, suggesting that CHF status was a
more powerful prognostic predictor. High sensitivity
cTnI remained significant; however, likely reflecting its
ability to detect myocardial cellular damage.39
Although the ability of cardiac biomarkers to discrimi-
nate between cardiac and respiratory causes of tachyp-
nea in cats is well-established,17–19,23,40,41 our results
show the additional prognostic value of measuring
cTnI in cats with HCM and CHF.
In the second model, CHF status and echocardio-
graphic data were included in the multivariable analysis.
The model that best accounted for differences in MST
included the presence of CHF, LA : Ao and cTnI. If LV
regional hypokinesis identified by 2D echocardiography
was included in the model, cTnI lost significance. This
suggests a close association between LV regional hypoki-
nesis and increased cTnI, similar to elevations in cardiac
troponins reported in humans with ischemic myocardial
damage.42,43 Regional LV hypokinesis is predictive of a
shorter survival time in cats with HCM10 and our results
suggest that indicators of myocardial damage (whether
increased cTnI concentration or regional LV hypokine-
sis) provide additional prognostic information indepen-
dent of the presence of CHF or LA dilatation.
The prognostic value of cTnI identified in our study
is similar to reports in humans, and recently cats, with
HCM.26,27,30 Although our study enrolled a relatively
small number of cats, its prospective nature and high
event rate add to the statistical power.44 Similar stud-
ies in humans with HCM, although enrolling a greater
number of subjects, have reported a notably lower
event rate.26,27
Possible misclassification of cause of death (cardiac/
noncardiac) or CHF status is a limitation of this
study. Classification of death because of cardiac dis-
ease was likely to be relatively accurate for cats eutha-
nized with CHF or ATE by their primary veterinarian,
Table 3. Results of Cox multivariable analyzes, performed to reflect each of two clinical scenarios. In each, cTnI
provided independent predictive value for cardiac death in cats with HCM. The exception was where regional LV
hypokinesis was detected by 2D echocardiography.
Multivariable Model Variable HR 95% CI
P-
Value
AIC
value
Model 1: CHF status established, echocardiography
unavailable
CHF (yes) 17.4 3.84–78.6 <.001 114.2
cTnI (>0.7 ng/mL) 6.78 1.98–23.2 .002
Model 2.1: CHF status established, echocardiography
available
CHF (yes) 6.35 1.10–36.7 .039 111.0
cTnI (>0.7 ng/mL) 5.61 1.61–19.5 .007
LA : Ao (>1.76) 4.53 1.04–19.7 .044
Model 2.2: CHF status established, echocardiography
available
CHF (yes) 11.9 2.60–54.4 .001 104.0
Regional LV hypokinesis
(yes)
16.3 2.71–97.6 .002
HCM, hypertrophic cardiomyopathy; HR, hazard ratio; 95% CI, 95% confidence intervals; AIC, Aikaike’s information criteria;
NTproBNP, N-terminal of pro-B-type natriuretic peptide; cTnI, cardiac troponin I; CHF, congestive heart failure; LA : Ao, left atrium
to aortic root ratio; LV, left ventricular.
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but may have been less accurate when based on owner
reports for cats that died at home. Further limitations
include a potential bias of owners or veterinarians in
the decision making process surrounding euthanasia,
lack of standardization in treatment, and the exclusion
of cats with comorbidities that may elevate biomarker
concentrations. Although this latter point may limit
the applicability of these results to a more heteroge-
neous feline population in clinical practice, it should
make these findings more accurate when considering
cats with HCM.
In conclusion, the key finding from this study is
that, although NTproBNP did not remain an indepen-
dent predictor of death because of cardiac disease, a
circulating concentration of cTnI >0.7 ng/mL was a
significant predictor of cardiac death in cats with
HCM that is independent of the presence of heart
failure or left atrial dilatation.
Footnotes
a Fox PR, Ettinger SJ, Lamb KE, et al. Evaluation of NTpro-
brain natriuretic peptide (NTproBNP) as a prognostic indica-
tors of short-term outcome in cats with heart failure. J Vet Int
Med 2013;27:637 (abstract)
b Queen Mother Hospital for Animals, Royal Veterinary College,
Hertfordshire, UK
c IDEXX Veterinary Laboratories, Wetherby, Yorkshire, UK
d AccuTnI, a paramagnetic particle chemiluminescent immunoas-
say from Access Immunoassay Systems (Ref. A78803), Beck-
man Coulter, High Wycombe, UK
e IBM SPSS 20 for Windows 7, IBM (UK) Ltd, Portsmouth,
UK; GraphPad Prism 6 for Windows 7, GraphPad Software
Inc., San Diego, CA
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